Beamtree Reports 9% Recurring Revenue Growth, $1M Singapore Contract, and UK Expansion

Strong Start to FY26

Beamtree Holdings Limited (ASX, BMT), a prominent player in AI-driven healthcare decision support, has kicked off FY26 with a solid 9% uplift in recurring revenue compared to the same quarter last year. This growth, amounting to an additional $570,000, underscores the company’s expanding footprint across multiple product lines and geographies.

Key contributors to this momentum include a $1 million clinical coding audit contract with Singapore’s Ministry of Health, which spans both public and private hospital sectors and highlights Beamtree’s growing presence in Asia. Additionally, the Knowledge Networks segment saw robust subscription growth, accounting for over a quarter of the revenue increase, while the PICQ Audit and RippleDown products also delivered strong contract wins and new licenses.

International Expansion and Product Innovation

Beamtree is actively advancing its strategic roadmap, particularly with the rollout of its autonomous clinical coding solution across Australia, Canada, and the UK. This next-generation product, targeting a global market valued at approximately US$22 billion, is priced significantly higher than legacy offerings, positioning the company for accelerated revenue and margin growth starting in Q3 FY26.

In the UK, Beamtree’s collaboration with the NHS Confederation through the Evolve platform is on track for launch in Q3 FY26. This initiative aims to replicate the company’s successful Australian and New Zealand membership model across England, Wales, and Northern Ireland, potentially unlocking broader adoption within the NHS and reinforcing Beamtree’s commitment to the UK healthcare market.

Financial Discipline and Leadership Strengthening

Despite increased investment in software development, up 40% to around $0.8 million in Q1, the company maintained strong cost discipline, reducing overall costs by 2% compared to the prior year quarter. This efficient reinvestment strategy supports ongoing product innovation and international expansion without compromising financial stability.

Further bolstering its growth ambitions, Beamtree appointed Stuart MacDonald as a Non-Executive Director. With over 15 years of global experience in listed software companies and a track record of scaling enterprise sales and international operations, MacDonald’s addition to the board is expected to accelerate Beamtree’s product and market expansion efforts.

Outlook

With a maturing sales pipeline, ongoing procurement negotiations across multiple regions, and a disciplined approach to capital allocation, Beamtree’s management expresses confidence in continued financial improvement throughout FY26. The company remains focused on profitable growth, leveraging its AI-driven healthcare solutions to capture new opportunities in key international markets.